Th17/Treg细胞在原发性胆汁性肝硬化发病中的作用研究进展*

doi:10.3969/j.issn.1672-5069.2015.02.031

摘要/Abstract

摘要： 原发性胆汁性肝硬化（PBC）属于一种病因未明的自身免疫性疾病。Th17细胞及Treg细胞是CD4⁺T细胞的两个亚群,分别起着抑制、促进炎症反应的作用,它们在分化和功能上相互抑制。PBC作为肝脏特异性的自身免疫性疾病,诸多研究提示Th17和Treg细胞数量及相关细胞因子在PBC患者中较健康者有差别,但其具体机制仍不清楚。近年来,它们在PBC发病中的变化越来越成为研究的热点。本文重点介绍Treg细胞和Th17细胞的研究现状及其在PBC发病机制中的作用。

关键词: 原发性胆汁性肝硬化, Th17细胞, Treg细胞

Abstract: Primary biliary cirrhosis（PBC） is a kind of autoimmune diseases with unknown etiology. Th17 cells and Treg cells are two subpopulations of CD4⁺T cells,plays suppression of,or promotion of inflammatory reactions respectively. They inhibit each other in the differentiation and function. Many studies suggest that Th17 and Treg cells,and related cytokines differ in PBC patients from in healthy persons,but the exact mechanism remains unclear. In recent years,their changes in the pathogenesis of PBC has become a hot topic. This review focuses on the research about Treg cells and Th17 cells and their roles in the pathogenesis of PBC.

Key words: Primary biliary cirrhosis, Th17 cells, Treg cells

苏兰, 杨晋辉, 唐映梅. Th17/Treg细胞在原发性胆汁性肝硬化发病中的作用研究进展*[J]. 实用肝脏病杂志, 2015, 18(2): 213-216.

Su Lan, Yang Jinhui. T helper type 17 and T regulatory cells in primary biliary cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 213-216.

参考文献

[1] 刘海英,姚定康,屠小卿,等. 原发性胆汁性肝硬化患者中自身抗原丙酮酸脱氢酶特异性CD8 + CTL表位预测及鉴定. 中国医学科学院学报,2004,26（5）：500-504.
[2] 高会霞,刘玉珍,袁文芳. 原发性胆汁性肝硬化患者调节性T细胞及相关细胞因子与肝功能损伤的相关性研究.现代中西医结合杂志,2012,21（4）：345-347.
[3] Zhu J,Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res,2010,20（1）:4-12.
[4] Park H,Li Z,Yang XO,et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol,2005,6（11）:1133-1141.
[5] Bian Z,Guo Y,Ha B,et al. Regulation of the inflammatory response:enhancing neutrophil infiltration under chronic inflammatory conditions. J Immunol,2012,188（2）:844-853.
[6] 徐维家,李志,杨婷婷,等. 系统性红斑狼疮患者Th17 和Th1 细胞及其细胞因子水平的变化及临床意义. 检验医学,2013,28（5）:396-399.
[7] Weaver CT,Harrington LE,Mangan PR,et al. Th17:an effector CD4 T cell lineage with regulatory T cell ties. Immunity,2006,24（6）:677-688.
[8] Mckarns SC,Schwartz RH. Distinct effects of TGF-beta 1 on CD4 + and CD8 + T cell survival,division,and IL-2 production:a role for T cell intrinsic Smad3. J Immunol,2005,174（4）:2071-2083.
[9] Ivanov II,McKenzie BS,Zhou L,et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+T helper cells. Cell,2006,126（6）:1121-1133.
[10] Mangan PR,Harrington LE,O'Quinn DB,et al. Transforming growth factor-beta induces development of the T（H）17 lineage. Nature,2006,441（7090）:231-234.
[11] Bettelli E,Carrier Y,Gao W,et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature,2006,441（7090）:235-238.
[12] Zhou L,Ivanov II,Spolski R,et al. IL-6 programs T（H）-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol,2007,8（9）:967-974.
[13] McGeachy MJ,Chen Y,Tato CM,et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol,2009,10（3）:314-324.
[14] Muratori L,Longhi MS. The interplay between regulatory and effector T cells in autoimmune hepatitis:Implications for innovative treatment strategies. J Autoimmun,2013,46:74-80.
[15] Lafdil F,Miller AM,Ki SH,et al. Th17 cells and their associated cytokines in liver diseases. Cell Mol Immunol,2010,7（4）:250-254.
[16] Zhao L,Qiu de K,Ma X. Th17 cells:the emerging reciprocal partner of regulatory T cells in the liver. J Dig Dis,2010,11（3）:126-33.
[17] Hammerich L,Heymann F,Tacke F. Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol,2011,2011:345803.
[18] Ye C,Li WY,Zheng MH,et al. T-helper 17 cell:a distinctive cell in liver diseases. Hepatol Res, 2011, 41（1）:22-29.
[19] Lan RY,Salunga TL,Tsuneyama K,et a1. Hepatic IL-17responses in human and murine primary biliary cirhosis. J Autoimmun,2009,32（1）:43-51.
[20] Rong G,Zhou Y,Xiong Y,et a1. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis:the serum cytokine profile and peripheral cell population.Clin Exp Immunol,2009,156（2）:217-225.
[21] Harada K, Shimoda S,Sato Y,et al. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol,2009,157（2）:261-270.
[22] 邓日辉, 周迎春, 陈曲波. 白细胞介素-1β和白细胞介素-23对原发性胆汁性肝硬化患者Th17细胞的影响.广东医学,2014,35（8）:1238-1240.
[23] Wakabayashi K,Lian ZX,Moritoki Y,et al. IL-2 receptor α -/- mice and the development of primary biliary cirrhosis. Hepatology,2006,44（5）:1240-1249.
[24] 彭辉,陈维贤,陈敏. IL-17与B淋巴细胞刺激因子在原发性胆汁性肝硬化患者中的表达及临床意义. 临床检验杂志,2011,29（4）:254-256.
[25] Sakaguchi S,Sakaguchi N,Asano M,et a1. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains（CD25）. Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J lmmunol,1995,155（3）:1151-1164.
[26] Sakaguchi S,Toda M,Asano M,et a1. T cell-mediated maintenance of natural self-tolerance:its breakdown as a possible cause of various autoimmune diseases. J Autoimmun,1996,9（2）:211-220.
[27] Sakaguchi S,Miyara M,Costantino CM,et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol, 2010,10（7）:490-500.
[28] Sakaguchi S. Naturally arising CD4 + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol,2004,22:531-562.
[29] Bernuzzi F,Fenoglio D,Battaglia F,et al. Phenotypical and functional alterations of CD8 + regulatory T cells in primary biliary cirrhosis. J Autoimmun,2010,35（3）:176-180.
[30] Liu B,Shi XH,Zhang FC,et al. Antimitochondrial antibody-negative primary biliary cirrhosis:a subset of primary biliary cirrhosis. Liver Int,2008,28（2）:233-239.
[31] 许茵,杨小娟,蒯守刚. 原发性胆汁性肝硬化患者外周血CD4+CD25 + Foxp3 + 调节性T细胞检测及其临床意义. 中国实验诊断学,2014,18（4）:592-594.
[32] Sasaki M,Ikeda H,Sawada S,et al. Naturally-occurring regulatory T cells are increased in inflamed portal tracts with cholangiopathy in primary biliary cirrhosis. J Clin Pathol,2007,60（10）:1102-1107.
[33] Bernuzzi F,Fenoglio D,Battaglia F,et al. Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. J Autoimmun,2010,35（3）:176-180.
[34] 王兰,杨瑞宁,张丽. Th17细胞和调节性T细胞与自身免疫性肝病的关系. 国际检验医学杂志,2014,35（8）:1022-1025.
[35] Reizis B,Colonna M,Trinchieri G,et al. Plasmacytoiddendritic cells:one-trick ponies or workhorses of the immune system Nat Rev Immunol,2011,11（8）:558-565.
[36] Gautreau L,Chabannes D,Heslan M,et al. Modulationof regulatory T cell-Th17 balance by plasmacytoid dendritic cells. J Leukoc Biol,2011,90（3）:521-527.
[37] Voo KS,Wang YH,Santori FR,et al. Identification of IL-17-producing FOXP3 + regulatory T cells in humans. Proc Natl Acad Sci U S A,2009,106（12）:4793-4798.
[38] Lina C,Conghua W,Nan L,et al. Combined treatment of etanercept and MTX reverses Th1/Th2,Th17/Treg imbalance in patients with rheumatoid arthritis. J Clin Immunol,2011,31（4）:596-605.
[39] Fenoglio D,Bernuzzi F,Battaglia F,et al. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmun Rev,2012,12（2）:300-304.
[40] Bernuzzi F,Fenoglio D,Battaglia F,et al. Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. J Autoimmun,2010,35（3）:176-180.